Close Menu
    Facebook LinkedIn YouTube Instagram X (Twitter)
    Blue Tech Wave Media
    Facebook LinkedIn YouTube Instagram X (Twitter)
    • Home
    • Leadership Alliance
    • Exclusives
    • Internet Governance
      • Regulation
      • Governance Bodies
      • Emerging Tech
    • IT Infrastructure
      • Networking
      • Cloud
      • Data Centres
    • Company Stories
      • Profiles
      • Startups
      • Tech Titans
      • Partner Content
    • Others
      • Fintech
        • Blockchain
        • Payments
        • Regulation
      • Tech Trends
        • AI
        • AR/VR
        • IoT
      • Video / Podcast
    Blue Tech Wave Media
    Home » AstraZeneca in AI collaboration with Immunai to inform cancer drug trials
    AstraZeneca-9.27
    AstraZeneca-9.27
    AI

    AstraZeneca in AI collaboration with Immunai to inform cancer drug trials

    By Heidi LuoSeptember 27, 2024No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email
    • AstraZeneca is investing $18 million in Immunai Inc to use AI to improve the efficiency of cancer drug trials.
    • The collaboration will improve clinical decision-making in oncology, focusing on dose selection and biomarker identification.

    OUR TAKE
    AstraZeneca has entered into an $18 million agreement with Immunai to use its artificial intelligence model to improve the efficiency of its cancer drug trials. The collaboration is part of AstraZeneca’s continued efforts to integrate AI into drug development, following a significant $247 million deal last year to develop cancer-fighting antibodies. Immunai, a New York-based biotech company, specialises in decoding the immune system using single-cell genomics and AI to revolutionise clinical decision-making in oncology.
    –Heidi Luo, BTW reporter

    What happened

    AstraZeneca has announced an $18 million collaboration with New York-based biotechnology company Immunai to use its advanced AI model of the immune system. The partnership aims to streamline cancer drug development and make clinical trials more efficient.

    Founded in 2018, Immunai combines single-cell genomics and machine learning to improve the development of new therapeutics by comprehensively analysing the immune system.

    In the first phase of the collaboration, AstraZeneca will gain access to Immunai’s state-of-the-art AI platform. This access is expected to provide AstraZeneca with valuable insights into the mechanisms of action of immunotherapies.

    According to AstraZeneca’s chief data scientist for oncology R&D, Iker Huerga, the collaboration will focus on key areas of clinical decision-making, including dose selection and biomarker identification, which are critical to optimising treatment efficacy.

    Also read: Appfire’s owners explore stake sale in collaboration software maker

    Also read: OpenAI fights misinformation with tech collaboration

    Why it’s important

    By integrating Immunai’s AI model, AstraZeneca aims not only to increase the efficiency of its drug trials, but also to improve its ability to more accurately predict treatment outcomes. This strategic move is expected to accelerate the time to market for its cancer therapies, potentially leading to more rapid advances in treatment options for patients.

    The partnership also underscores the critical role of AI in transforming the pharmaceutical landscape, particularly in the area of personalised medicine. By focusing on dose selection and biomarker identification, AstraZeneca is paving the way for more personalised treatment plans that meet the needs of individual patients.

    The ability to decode and manipulate complex immune responses using AI could lead to breakthroughs in understanding how different cancers respond to different therapies. The collaboration between AstraZeneca and Immunai sets a precedent for the future of AI in improving drug discovery and development processes across the industry.

    AstraZeneca cancer drug trials Immunai
    Heidi Luo

    Heidi Luo is an intern reporter at Blue Tech Wave specialising in IT and tech trends. She graduated from Cardiff University. Send tips to h.luo@btw.media

    Related Posts

    Orange Business: Unveils defence division

    July 11, 2025

    AFRINET SA: Expands digital services in the DRC

    July 10, 2025

    Vodafone and Digital Realty launch subsea hub in Crete

    July 10, 2025
    Add A Comment
    Leave A Reply Cancel Reply

    CATEGORIES
    Archives
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • September 2023
    • August 2023
    • July 2023

    Blue Tech Wave (BTW.Media) is a future-facing tech media brand delivering sharp insights, trendspotting, and bold storytelling across digital, social, and video. We translate complexity into clarity—so you’re always ahead of the curve.

    BTW
    • About BTW
    • Contact Us
    • Join Our Team
    TERMS
    • Privacy Policy
    • Cookie Policy
    • Terms of Use
    Facebook X (Twitter) Instagram YouTube LinkedIn

    Type above and press Enter to search. Press Esc to cancel.